MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiayu, Li, Xuefei, Ren, Shengxiang, Chen, Xiaoxia, Zhang, Yishi, Zhou, Fei, Zhao, Mingchuan, Zhao, Chao, Chen, Xiu, Cheng, Ningning, Zhao, Yinmin, Zhou, Caicun, Hirsch, Fred R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202169/
https://www.ncbi.nlm.nih.gov/pubmed/25277203

Ejemplares similares

Ejemplares similares